JPMorgan Chase & Co. lessened its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 7.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 192,699 shares of the company's stock after selling 15,023 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.27% of Kymera Therapeutics worth $10,907,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in KYMR. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Kymera Therapeutics by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company's stock worth $849,000 after acquiring an additional 1,833 shares in the last quarter. Millennium Management LLC increased its stake in shares of Kymera Therapeutics by 340.4% in the 1st quarter. Millennium Management LLC now owns 510,480 shares of the company's stock valued at $13,972,000 after purchasing an additional 394,562 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Kymera Therapeutics by 121.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company's stock worth $24,535,000 after purchasing an additional 491,737 shares during the period. PNC Financial Services Group Inc. raised its holdings in Kymera Therapeutics by 506.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company's stock worth $40,000 after purchasing an additional 770 shares during the period. Finally, Legal & General Group Plc boosted its position in Kymera Therapeutics by 3.7% during the second quarter. Legal & General Group Plc now owns 41,523 shares of the company's stock worth $1,812,000 after purchasing an additional 1,486 shares in the last quarter.
Insider Transactions at Kymera Therapeutics
In other Kymera Therapeutics news, Director Bruce Booth sold 81,866 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $90.13, for a total value of $7,378,582.58. Following the completion of the sale, the director owned 675,341 shares in the company, valued at approximately $60,868,484.33. This represents a 10.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Nello Mainolfi sold 30,000 shares of the firm's stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $90.26, for a total transaction of $2,707,800.00. Following the completion of the transaction, the chief executive officer directly owned 666,195 shares in the company, valued at $60,130,760.70. This trade represents a 4.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 312,538 shares of company stock valued at $26,145,679. Company insiders own 16.01% of the company's stock.
Kymera Therapeutics Price Performance
Shares of Kymera Therapeutics stock opened at $78.16 on Friday. The business has a 50 day simple moving average of $80.23 and a two-hundred day simple moving average of $70.86. Kymera Therapeutics, Inc. has a 12 month low of $19.44 and a 12 month high of $103.00. The stock has a market capitalization of $6.38 billion, a P/E ratio of -21.24 and a beta of 2.20.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The firm had revenue of $2.87 million during the quarter, compared to analyst estimates of $14.80 million. During the same period in the prior year, the firm earned ($0.88) earnings per share. The business's revenue was down 60.8% on a year-over-year basis. As a group, research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of research firms have recently commented on KYMR. Weiss Ratings restated a "sell (d-)" rating on shares of Kymera Therapeutics in a research report on Thursday, January 22nd. HC Wainwright increased their target price on Kymera Therapeutics from $84.00 to $134.00 and gave the company a "buy" rating in a research report on Tuesday, December 9th. Oppenheimer lifted their price target on shares of Kymera Therapeutics from $67.00 to $120.00 and gave the company an "outperform" rating in a research note on Tuesday, December 9th. BTIG Research cut their price target on shares of Kymera Therapeutics from $138.00 to $134.00 and set a "buy" rating for the company in a report on Thursday, February 26th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Kymera Therapeutics from $70.00 to $125.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 10th. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $118.90.
Check Out Our Latest Stock Analysis on KYMR
About Kymera Therapeutics
(
Free Report)
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company's pipeline emphasizes immunology and oncology.
Further Reading
Want to see what other hedge funds are holding KYMR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kymera Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kymera Therapeutics wasn't on the list.
While Kymera Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
